Abstract:Key PointsScientific advancement in neuroscience has not been effectively translated into therapies for neurological diseases. In general, 'toxin reducing' approaches (for example, lowering amyloid-β (Aβ)) thus far have not resulted in halting or delaying disease progression. A paradigm shift in the discovery of disease-modifying therapies for neurological diseases is urgently needed.For neurodegenerative diseases, targeting the pathophysiology rather than the pathogenesis may be more effective to achieve therapeutic intervention. The toxin reducing approach may work if treatment starts very early on in the disease process.Synapse degeneration is a major pathophysiological feature that correlates with disease progression in multiple neurodegenerative diseases. Neuronal loss is irreversible, whereas synapses can be repaired and regenerated.Three aspects of synaptic physiology can be targeted: synaptic transmission, synaptic plasticity and synaptic growth. For disease-modifying therapy, synaptic plasticity and, more importantly, synaptic growth should be targeted.Brain-derived neurotrophic factor (BDNF) is an exemplar of synaptic repair therapy, as it regulates all three aspects of synaptic physiology. It protects and repairs existing synapses and stimulates new synapse formation, even in the presence of various toxins.In humans, the BDNF Val66Met polymorphism in conjunction with high Aβ deposits confers faster decline in Alzheimer's disease endophenotypes such as episodic memory and hippocampal volume, and therefore could be considered as a patient stratification strategy for clinical trials with enhanced sensitivity and robustness.Success of a 'synaptic repair' therapy depends on whether synaptic dysfunction and synaptic repair and/or regeneration can be measured in the clinic. Efforts should be made to develop sensitive and reliable methodologies to measure synaptic function in humans in vivo.Opportunities and challenges in developing BDNF–TRKB pathway-based therapies, including delivery, are discussed.A combination of synaptic therapy and a more reliable and sensitive method (or methods) to measure synaptic changes may pave the way for developing disease-modifying medicines for debilitating neurological diseases. This Review highlights recent discoveries, discusses emerging concepts and proposes synapse-based therapies for treating neurodegenerative diseases.

Synaptic Secretion and Beyond: Targeting Synapse and Neurotransmitters to Treat Neurodegenerative Diseases

Synaptic Secretion and Beyond: Targeting Synapse and Neurotransmitters to Treat Neurodegenerative Diseases

Molecular Mechanoneurobiology: An Emerging Angle to Explore Neural Synaptic Functions

Targeting synapse function and loss for treatment of neurodegenerative diseases

Research Progress on Vesicle Cycle and Neurological Disorders

Synaptic Vulnerability in Neurodegenerative Disease

Present and future use of exosomes containing proteins and RNAs in neurodegenerative diseases for synaptic function regulation: A comprehensive review

Autophagy in Synaptic Development, Function, and Pathology

Neurons Specialize in Presynaptic Autophagy: A Perspective to Ameliorate Neurodegeneration

BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases

The role of synaptic protein NSF in the development and progression of neurological diseases

Epigenetic regulation of neurotransmitter signaling in neurological disorders

Presynaptic Perspective: Axonal Transport Defects in Neurodevelopmental Disorders.

Dysfunctional Autophagy and Endolysosomal System in Neurodegenerative Diseases: Relevance and Therapeutic Options

The synapse as a treatment avenue for Alzheimer’s Disease

Synapse formation: from cellular and molecular mechanisms to neurodevelopmental and neurodegenerative disorders

New Insights into Molecular Mechanisms Underlying Neurodegenerative Disorders

Common mechanisms underlying axonal transport deficits in neurodegenerative diseases: a mini review

Targeting the Synapse in Alzheimer’s Disease

The Role of Vesicle Release and Synaptic Transmission in Depression

Regulation of Synaptic Transmission through Mitochondrial Positioning and Metabolism